167 related articles for article (PubMed ID: 21205947)
1. Intravenous N-acetylcysteine in the prevention of contrast media-induced nephropathy.
Anderson SM; Park ZH; Patel RV
Ann Pharmacother; 2011 Jan; 45(1):101-7. PubMed ID: 21205947
[TBL] [Abstract][Full Text] [Related]
2. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
[TBL] [Abstract][Full Text] [Related]
3. Multimodality prevention of contrast-induced acute kidney injury.
McCullough PA
Am J Kidney Dis; 2008 Feb; 51(2):169-72. PubMed ID: 18215694
[No Abstract] [Full Text] [Related]
4. Prevention of contrast-induced nephropathy in patients undergoing emergent coronary procedures.
Bouzas-Mosquera A; Vázquez-Rodríguez JM
Am J Cardiol; 2008 Mar; 101(6):910. PubMed ID: 18328863
[No Abstract] [Full Text] [Related]
5. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study.
Baker CS; Wragg A; Kumar S; De Palma R; Baker LR; Knight CJ
J Am Coll Cardiol; 2003 Jun; 41(12):2114-8. PubMed ID: 12821233
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, randomized, controlled trial on N-acetylcysteine for the prevention of acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ataei S; Hadjibabaie M; Moslehi A; Taghizadeh-Ghehi M; Ashouri A; Amini E; Gholami K; Hayatshahi A; Vaezi M; Ghavamzadeh A
Hematol Oncol; 2015 Jun; 33(2):67-74. PubMed ID: 24711000
[TBL] [Abstract][Full Text] [Related]
7. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty.
Marenzi G; Assanelli E; Marana I; Lauri G; Campodonico J; Grazi M; De Metrio M; Galli S; Fabbiocchi F; Montorsi P; Veglia F; Bartorelli AL
N Engl J Med; 2006 Jun; 354(26):2773-82. PubMed ID: 16807414
[TBL] [Abstract][Full Text] [Related]
8. Reno-protective effect of N-acetyl cysteine in patients with impaired renal function undergoing coronary angiography and interventions.
Ramesh N; Pillai RK; Abraham T; Padmaja NP; Hameed S; Vijayaraghavan G
J Assoc Physicians India; 2006 Jun; 54():449-52. PubMed ID: 16909692
[TBL] [Abstract][Full Text] [Related]
9. The role of theophylline in prevention of radiocontrast media-induced nephropathy.
Malhis M; Al-Bitar S; Al-Deen Zaiat K
Saudi J Kidney Dis Transpl; 2010 Mar; 21(2):276-83. PubMed ID: 20228513
[TBL] [Abstract][Full Text] [Related]
10. New pharmacological protocols to prevent or reduce contrast media nephropathy.
Briguori C; Airoldi F; Morici N; Colombo A
Minerva Cardioangiol; 2005 Feb; 53(1):49-58. PubMed ID: 15788979
[TBL] [Abstract][Full Text] [Related]
11. Novel approach for the prevention of contrast nephropathy.
Colbay M; Yuksel S; Uslan I; Acarturk G; Karaman O; Bas O; Mollaoglu H; Yagmurca M; Ozen OA
Exp Toxicol Pathol; 2010 Jan; 62(1):81-9. PubMed ID: 19327972
[TBL] [Abstract][Full Text] [Related]
12. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine.
Tepel M; van der Giet M; Schwarzfeld C; Laufer U; Liermann D; Zidek W
N Engl J Med; 2000 Jul; 343(3):180-4. PubMed ID: 10900277
[TBL] [Abstract][Full Text] [Related]
13. N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best?
Shalansky SJ; Vu T; Pate GE; Levin A; Humphries KH; Webb JG
Pharmacotherapy; 2005 Aug; 25(8):1095-103. PubMed ID: 16207100
[TBL] [Abstract][Full Text] [Related]
14. Contrast medium-induced nephropathy: strategies for prevention.
Massicotte A
Pharmacotherapy; 2008 Sep; 28(9):1140-50. PubMed ID: 18752385
[TBL] [Abstract][Full Text] [Related]
15. Acetylcysteine and renal function following coronary angiographic procedures.
Bagshaw SM; Culleton BF
JAMA; 2003 Jun; 289(21):2795; author reply 2796. PubMed ID: 12783908
[No Abstract] [Full Text] [Related]
16. Acetylcysteine and renal function following coronary angiographic procedures.
Balderramo DC
JAMA; 2003 Jun; 289(21):2795-6; author reply 2796. PubMed ID: 12783907
[No Abstract] [Full Text] [Related]
17. Amikacin-induced nephropathy: is there any protective way?
Kaynar K; Gul S; Ersoz S; Ozdemir F; Ulusoy H; Ulusoy S
Ren Fail; 2007; 29(1):23-7. PubMed ID: 17365906
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.
Toso A; Maioli M; Leoncini M; Gallopin M; Tedeschi D; Micheletti C; Manzone C; Amato M; Bellandi F
Am J Cardiol; 2010 Feb; 105(3):288-92. PubMed ID: 20102936
[TBL] [Abstract][Full Text] [Related]
19. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
Kim BJ; Sung KC; Kim BS; Kang JH; Lee KB; Kim H; Lee MH
Int J Cardiol; 2010 Feb; 138(3):239-45. PubMed ID: 18793808
[TBL] [Abstract][Full Text] [Related]
20. Contrast media nephropathy--how to diagnose and how to prevent?
Solomon R
Nephrol Dial Transplant; 2007 Jul; 22(7):1812-5. PubMed ID: 17449491
[No Abstract] [Full Text] [Related]
[Next] [New Search]
